0351 GMT - Biopharmaceutical company CSL and medical equipment firm Resmed have the best combination of attractive valuation and low tariff impact among Australian healthcare stocks, suggests Morgan Stanley equity analyst David L. Bailey. He estimates that CSL would need to raise prices by 1% and Resmed would need to raise prices by 2%-3% to offset the earnings impact from tariffs. But given their solid earnings per share growth, low earnings risk and valuation appeal, he says these companies are the "most favorably positioned" among peers. One word of caution--pharmaceuticals are currently excluded from reciprocal tariffs, but Trump has signaled he wants to put tariffs on that sector soon, which could impact CSL. (mike.cherney@wsj.com; @Mike_Cherney)
(END) Dow Jones Newswires
April 14, 2025 23:51 ET (03:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。